PicoCELA Inc. (NASDAQ:PCLA) Sees Large Increase in Short Interest

PicoCELA Inc. (NASDAQ:PCLA) was the target of a large increase in short interest in July. As of July 15th, there was short interest totaling 201,780 shares, an increase of 77.2% from the June 30th total of 113,864 shares. Approximately 504.5% of the company’s stock are short sold. Based on an average daily volume of 503,315 shares, the short-interest ratio is currently 0.4 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC bought a new position in PicoCELA Inc. (NASDAQ:PCLA) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned approximately 18.92% of PicoCELA as of its most recent SEC filing.

Analyst Upgrades and Downgrades

PCLA has been the topic of several analyst reports. Wall Street Zen upgraded PicoCELA to a “hold” rating in a report on Saturday, July 25th. Weiss Ratings upgraded PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has an average rating of “Sell”.

PicoCELA Stock Performance

NASDAQ:PCLA opened at $4.91 on Friday. PicoCELA has a 12-month low of $1.35 and a 12-month high of $16.80. The business has a 50 day simple moving average of $5.77 and a 200 day simple moving average of $4.31.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.